[Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
To evaluate the clinical usefulness of CYFRA21-1 as a serum tumor marker in diagnosis, evaluation of clinical status and prognosis of patients with non-small-cell lung cancer (NSCLC). CYFRA21-1 in 126 serum samples of NSCLC patients was measured by radioimmunoassay. Of the 126 samples, 71 were collected before treatment, 29 at two weeks after operation, and 26 after 15-18 months follow-up. CYFRA21-1 was positive in 49.3% of the NSCLC patients who had not received any treatment. The positive rate was 69.2% for squamous-cell carcinoma, and 25.0% for adenocarcinoma. The serum level of CYFRA21-1 was significantly higher in squamous-cell carcinoma than in adenocarcinoma (P < 0.0001). The serum level of CYFRA21-1 well correlated and increased with TNM staging (P = 0.0001). The level decreased significantly within two weeks after surgical operation in 29 cases (P = 0.0005). On follow up for 15-18 months, no change in CYFRA21-1 level was observed in 16 patients whose disease was stable, while there was significant increase in 10 patients with progressive disease. CYFRA21-1 is a soluble fragment of cytokeratin 19 in serum of patients with NSCLC. It can be used as a useful tumor marker of NSCLC.